Biodistribution and pharmacokinetics, safety and therapeutic effect of the CIGB-300 application in the epidermoid carcinoma of the uterine neck stage IB2-II

Trial Profile

Biodistribution and pharmacokinetics, safety and therapeutic effect of the CIGB-300 application in the epidermoid carcinoma of the uterine neck stage IB2-II

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs CIGB 300 (Primary)
  • Indications Cervical cancer
  • Focus Pharmacokinetics
  • Acronyms CERVIFARM-300-II
  • Most Recent Events

    • 23 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record
    • 18 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top